Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505
Figure 1 Flow diagram showing patient screening, enrollment, exclusions, and study completion.
A total of 84 patients were assessed for eligibility, 79 were enrolled, and 67 completed the study. SGLT2i: Sodium-glucose cotransporter 2 inhibitor.
- Citation: Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505
- URL: https://www.wjgnet.com/1948-5182/full/v18/i10/125505.htm
- DOI: https://dx.doi.org/10.4254/wjh.125505